Summary: In a 12-week pilot randomised trial of 30 adults with type 2 diabetes, an 800 kcal/day very-low calorie diet (VLCD) and the VLCD-plus-semaglutide combination produced significantly greater weight and fat-mass loss than semaglutide alone (5.4 and 7 percentage points more, respectively; p<0.01). Adding semaglutide to the VLCD gave no extra weight benefit over the diet alone but did improve pancreatic beta-cell function.
PICO Summary
| Element | Detail |
|---|---|
| Population | 30 adults with type 2 diabetes, aged 18-75 years, BMI 27-50 kg/m²; single-centre pilot randomised controlled trial, United Kingdom. |
| Intervention | 800 kcal/day very-low calorie diet (VLCD) alone, or VLCD combined with semaglutide (COMB), for 12 weeks; roughly 10 participants per arm. |
| Comparison | Semaglutide alone (SEM) for 12 weeks; roughly 10 participants. |
| Outcome | VLCD and COMB achieved 5.4 and 7 percentage-point greater weight loss than SEM (p<0.01 versus both). HbA1c and fasting glucose fell in all three arms; fasting insulin and HOMA-IR improved in VLCD and COMB only. First-phase insulin response rose in SEM and COMB, with a greater increase in COMB than VLCD (p<0.01). COMB added no weight or body-composition benefit over VLCD alone. No 95% confidence intervals, absolute risk reduction, or number-needed-to-treat were reported for this exploratory pilot. |
VLCD, Semaglutide, or Both in Type 2 Diabetes
Pilot RCT · type 2 diabetes · 12 weeks
Short-term weight and fat-mass loss were driven mainly by the very-low calorie diet, not semaglutide. Adding semaglutide to the diet gave no extra weight benefit but improved beta-cell function. Pilot only (~10 per arm), so estimates are fragile.
Expert Commentary
This is an exploratory pilot trial, and its findings should be read as hypothesis-generating rather than as confirmed efficacy. With only about ten participants per arm, the study was designed to probe direction and feasibility, not to deliver definitive between-group estimates, and no confidence intervals were reported for the headline differences. Within those limits, the signal is coherent: short-term weight and fat-mass loss were driven mainly by the caloric deficit of the very-low calorie diet, while semaglutide alone produced more modest reductions over twelve weeks. The most interesting observation is the apparent complementarity, where the diet did the heavy lifting on weight while the combination further enhanced first-phase insulin response, a marker of beta-cell function. The dominant limitation is sample size, which leaves these point estimates fragile and vulnerable to a few individual responders. Can I use this with my patients? Not yet as a protocol, though it reinforces a familiar message for a motivated adult with type 2 diabetes and obesity that structured caloric restriction remains a powerful lever, and that pairing it with a GLP-1 receptor agonist is biologically plausible. Adequately powered, longer trials with confidence intervals and durability data are needed before the combination is recommended over diet alone. No manufacturer sponsorship was declared in the abstract.
References
Anyiam O, Phillips B, Quinn K, Wilkinson D, Smith K, Atherton P, Idris I. Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus. Clin Nutr. 2024;43(8):1907-1913. doi:10.1016/j.clnu.2024.06.034